Home › Research › Biomarkers
Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes
Frey KA, Petrou M.. Clinical and translational imaging, 2015-02-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Dementia arising in patients with Parkinson disease or parkinsonian neurodegeneration comprises a heterogeneous neuropathology. Clinical labeling of patients with both dementia and Parkinson disease is dichotomous, depending on the temporal development of cognitive impairment and motor parkinsonism. Patients with dementia arising first (or within the first year of PD) are classified as dementia with Lewy bodies; patients with PD for more than one year before cognitive decline are classified as Parkinson disease with dementia. Despite this differential clinical classification, autopsy studies demonstrate variable admixtures of cortical synuicleinopathy, Aβ-amyloidopathy and tau neurofibrillary tangle deposition. There are no routine clinical diagnostic measures that accurately distinguish the underlying neuropathologies in individual patients. In the present paper, we review the published literature describing characteristics of fibrillary Aβ-amyloid deposition on the basis of PET radiotracer imaging in patients with Parkinson disease and in parkinsonian dementia syndromes. Although individual reports often include only small-to-modest subject numbers, there is overall suggestion that PD patients have a lower incidence of Aβ-amyloid deposition than seen amongst elderly normal subjects, and that Parkinson disease with dementia patients have a lower incidence of Aβ-amyloid deposition than do patients with dementia with Lewy bodies. These apparent features contrast the findings of Aβ-amyloid-PET imaging in normal aging and the development of Alzheimer disease, where Aβ-amyloid deposition arises asymptomatically and apparently many years before development of signs or symptoms of dementia. It is proposed that focused, prospective studies are needed to further address and understand the complex role(s) of Aβ-amyloid pathology in Parkinson disease, and that this understanding will be critical to the development of targeted disease-modifying therapy for dementia in PD.
What this study adds
Evidence grade: Low
This review of PET amyloid imaging studies suggests that people with Parkinson disease have a lower incidence of amyloid deposition than elderly normal subjects, and that those with Parkinson disease with dementia also have a lower incidence. The reviewed reports often included only small-to-modest numbers of subjects.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Frey, K. A., & Petrou, M. (2015). Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes. Clinical and translational imaging. https://doi.org/10.1007/s40336-015-0104-4
Vancouver
Frey KA, Petrou M. Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes. Clinical and translational imaging. 2015. doi:10.1007/s40336-015-0104-4. PMID: 25745616.
BibTeX
@article{frey2015-25745616,
author = {Frey, K. A. and Petrou, M.},
title = {{Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes}},
journal = {Clinical and translational imaging},
year = {2015},
doi = {10.1007/s40336-015-0104-4},
pmid = {25745616},
url = {https://doi.org/10.1007/s40336-015-0104-4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Although individual reports often include only small-to-modest subject numbers, there is overall suggestion that PD patients have a lower incidence of Aβ-amyloid deposition than seen amongst elderly normal subjects, and that Parkinson disease with dementia patients have a lower incidence of Aβ-amyloid deposition than do patients with dementia with Lewy bodies.
Why it matters
This review of PET amyloid imaging studies suggests that people with Parkinson disease have a lower incidence of amyloid deposition than elderly normal subjects, and that those with Parkinson disease with dementia also have a lower incidence. The reviewed reports often included only small-to-modest numbers of subjects.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 32/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 31 of the 96 points we could judge it on, which is 32 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Clinical and translational imaging) |
| Journal's citation record | 0 / 4 | Clinical and Translational Imaging: journal h-index 46 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 25 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.9 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 2 / 6 | Cited 2.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | University of Michigan: institution h-index 2,240 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25745616) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 31 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 31 of the 96 points we could judge it on is 32 out of 100. |
| Total | 32 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 32.
Related studies in Biomarkers from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.